NCT00166452 is a Phase 3 clinical trial of Lenalidamide in Complex Regional Pain Syndrome, Type 1, sponsored by Mayo Clinic.

Who is sponsoring NCT00166452?

NCT00166452 is sponsored by Mayo Clinic.

What drugs are being tested in NCT00166452?

Interventions in NCT00166452: Lenalidamide.

What condition does NCT00166452 study?

NCT00166452 studies Complex Regional Pain Syndrome, Type 1.

Is NCT00166452 still recruiting?

NCT00166452 is currently completed. Last updated 22 March 2011.

Last reviewed 2011-03-22 · How we verify

NCT00166452

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Multicenter, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lenalidamide in the Treatment of Complex Regional Pain Syndrome Type1

Completed Phase 3 Last updated 22 March 2011

What this trial tests

Phase 3 trial testing Lenalidamide in Complex Regional Pain Syndrome, Type 1 in 7 participants. Completed in 1 February 2009.

Timeline

1 July 2005

Primary endpoint
1 April 2007

1 February 2009

Quick facts

Lead sponsor	Mayo Clinic
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	double
Primary purpose	treatment
Enrollment	7
Start date	1 July 2005
Primary completion	1 April 2007
Estimated completion	1 February 2009
Sites	1 location across United States

Drugs / interventions tested

Lenalidamide — full drug profile →

Conditions studied

Complex Regional Pain Syndrome, Type 1 — all drugs for Complex Regional Pain Syndrome, Type 1 →

Sponsor

Mayo Clinic

Who can join

18 and older, any sex, with Complex Regional Pain Syndrome, Type 1. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

RPS Pain Intensity Numeric Rating Scale (PI-NRS): At least 30% reduction from baseline

Sponsor's own description

The purpose of this study is to determine if lenalidomide is a safe and effective treatment for complex regional pain syndrome type 1 (CRPS).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Mayo Clinic trials

Trials by the same sponsor.

NCT07126548 — A Point of Prostate Cancer Diagnosis Virtual Reality Assistant Intervention in Supporting Newly Diagnosed Black Men · NA · not yet recruiting
NCT07221656 — Evaluation of Prolonged Asparaginase Activity Levels After Calaspargase Pegol Administration · not yet recruiting
NCT06891001 — The Utilization of a Shoe Insert on Individuals With Unilateral Greater Trochanteric Pain Syndrome on Single Leg Stance, · NA · not yet recruiting
NCT07169799 — Impact of Cryotherapy Spray (Tru-Freeze) for the Eradication of Gastric Antral Vascular Ectasia (ICE-GAVE) · NA · recruiting
NCT07086183 — Perioperative Risk in Patients on Chronic Aspirin Undergoing Craniotomy · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00166452 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Mayo Clinic
Last refreshed: 22 March 2011

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00166452.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing